Who are JR-141 or Idursulfase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RDD to Palynziq, creon 35.000 Ph.U (R), Cerezyme® / Imiglucerase, alpha-1-Proteinase Inhibitor, ALGLUCOSIDASE ALFA (MYOZYME), Pancreatic Enzyme.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/jr-141-or-idursulfase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

JR-141 or Idursulfase — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

JR-141 or Idursulfase (JR-141 or Idursulfase) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Enzyme replacement therapy. Area: Rare genetic disease / Lysosomal storage disorder.

phase 3 Enzyme replacement therapy Iduronate-2-sulfatase Rare genetic disease / Lysosomal storage disorder Small molecule Live · refreshed every 30 min

Target snapshot

JR-141 or Idursulfase (JR-141 or Idursulfase) — JCR Pharmaceuticals Co., Ltd.. JR-141 is a recombinant idursulfase enzyme that replaces deficient iduronate-2-sulfatase to break down glycosaminoglycans in Hunter syndrome.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
JR-141 or Idursulfase TARGET	JR-141 or Idursulfase	JCR Pharmaceuticals Co., Ltd.	phase 3	Enzyme replacement therapy	Iduronate-2-sulfatase
RDD to Palynziq	RDD to Palynziq	BioMarin Pharmaceutical	marketed	Enzyme replacement therapy	Phenylalanine ammonia-lyase (PAL)
creon 35.000 Ph.U (R)	creon 35.000 Ph.U (R)	Hospital Clinico Universitario de Santiago	marketed	Pancreatic enzyme replacement therapy
Cerezyme® / Imiglucerase	Cerezyme® / Imiglucerase	Sanofi	marketed	Enzyme replacement therapy	Glucocerebrosidase (β-glucosidase)
alpha-1-Proteinase Inhibitor	alpha-1-Proteinase Inhibitor	Institute for Human Genetics and Biochemistry	marketed	Protease inhibitor / Enzyme replacement therapy	Neutrophil elastase
ALGLUCOSIDASE ALFA (MYOZYME)	ALGLUCOSIDASE ALFA (MYOZYME)	Genzyme, a Sanofi Company	marketed	Enzyme replacement therapy	Acid alpha-glucosidase (GAA)
Pancreatic Enzyme	Pancreatic Enzyme	University of Oxford	marketed	Pancreatic enzyme replacement therapy (PERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). JR-141 or Idursulfase — Competitive Intelligence Brief. https://druglandscape.com/ci/jr-141-or-idursulfase. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab